Dexamethasone Versus Dexmedetomidine as Adjuvants for Nerve Blocks

April 29, 2019 updated by: Julian Aliste, University of Chile

A Randomized Comparison Between Perineural Dexamethasone and Perineural Dexmedetomidine as Adjuvants for Ultrasound-Guided Infraclavicular Blocks

When used as perineural (PN) adjuvants to local anesthetics (LAs), dexamethasone (DX) and dexmedetomidine (DXD) have been well documented to prolong the duration of peripheral nerve blocks. These drugs have important differences in terms of cost and safety profiles. This randomized controlled trial (RCT) will compare PN DX and PN DXD for ultrasound-guided infraclavicular brachial plexus blocks (ICBs).

Since analgesic and sensory duration can be influenced by factors different to block, motor block duration is the main outcome. The protocol is designed as an equivalency trial and hypothesize that both drugs result in similar durations. The equivalency margin is set at 3 hrs.

Study Overview

Study Type

Interventional

Enrollment (Actual)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Metropolitana
      • Santiago, Metropolitana, Chile, 8380456
        • Hospital Clinico Universidad de Chile

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • age between 18 and 75 years
  • American Society of Anesthesiologists classification 1-3
  • body mass index between 20 and 35

Exclusion Criteria:

  • adults who are unable to give their own consent
  • pre-existing neuropathy (assessed by history and physical examination)
  • coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets ≤ 100, International Normalized Ratio ≥ 1.4 or prothrombin time ≥ 50)
  • renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. creatinine ≥ 100)
  • hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. transaminases ≥ 100)
  • allergy to local anesthetics (LAs)
  • pregnancy
  • prior surgery in the infraclavicular region
  • chronic pain syndromes requiring opioid intake at home

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Perineural dexamethasone
addition of dexamethasone to local anesthetics in infraclavicular brachial plexus block
Dexamethasone as perineural local anesthetic adjuvant
Active Comparator: Perineural dexmedetomidine
addition of dexmedetomidine to local anesthetics in infraclavicular brachial plexus block
Dexmedetomidine as perineural local anesthetic adjuvant

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Motor block duration
Time Frame: 24 hours after block
Elapsed time since the end of LA injection until return of hand and fingers movement
24 hours after block

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sensory block duration
Time Frame: 24 hours after block
Elapsed time since the end of LA injection until return of hand and fingers sensation
24 hours after block
Analgesic block duration
Time Frame: 24 hours after block
Elapsed time since the end of LA injection until first sensation of pain in surgical area
24 hours after block
Block performance time
Time Frame: 1 hour before surgery
Elapsed time from skin desinfection until the end of LA injection
1 hour before surgery
Intensity of pain during block procedure
Time Frame: 1 hour before surgery
Evaluated with a numeric rating score from 0 to 10
1 hour before surgery
Block onset time
Time Frame: 1 hour before surgery
Time required to reach a minimal sensorimotor composite score of 14 points out of a maximum of 16 points
1 hour before surgery
Sensory and motor block score
Time Frame: 30 minutes post injection

Sensorimotor block assessed every 5 minutes until 30 minutes using a 16-point composite score evaluating sensory and motor block of musculocutaneus, medium, radial and ulnar nerves.

Sensation will be assessed with ice in each nerve territory with a 0 to 2 point scale. 0= no block, patients can feel cold; 1= analgesic block, patient can feel touch but not cold; 2= anesthetic block, patient cannot feel cold or touch.

Motor function will be assessed for each nerve with a 0 to 2 points scale where 0= no motor block; 1= paresis; 2= paralysis.

Succesfull blocks at 30 minutes correlate with a final score ( sum of all individual sensory and motor scores) of at least 14 points out of 16.

30 minutes post injection
Incidence of complete block
Time Frame: 30 minutes post injection
Percentage of blocks with a minimal sensorimotor composite score of 14 points out of a maximum of 16 points at 30 minutes post injection
30 minutes post injection
Perioperative glycemic levels
Time Frame: Perioperative period
Capillary dextrose measurements at pre block, 1 hour post-surgery and 6 hours post-surgery
Perioperative period
Perioperative median artery pressure (MAP)
Time Frame: 2 hours after surgery
Average of MAP and HR registered during preblock, intraoperative and up to 2 hours of postoperative period
2 hours after surgery
Perioperative heart rate (HR)
Time Frame: 2 hours after surgery
Average MAP registered during preblock, intraoperative and up to 2 hours of postoperative period
2 hours after surgery
Postoperative persistent sedation
Time Frame: 2 hours after surgery

Persistent sedation after surgery using Ramsay sedation scale.

1= anxious agitated or restless; 2= co-operative, oriented and tranquil; 3= responds to command only; 4= brisk response to light pain or loud auditory stimulus; 5= sluggish response to light pain or loud auditory stimulus; 6= no response.

2 hours after surgery
Respiratory depression
Time Frame: 2 hours after surgery
Low respiratory rate (lower than 8 breaths per minute) or persistent oxygen requirement (pulse oximetry lower than 90% without supplementary oxygen)
2 hours after surgery
Incidence of block side effects
Time Frame: 2 hours after surgery
Presence of paresthesia, local anesthetic systemic toxicity, vascular puncture, pneumothorax, hemidiaphragmatic paralysis, Horner syndrome or hoarseness
2 hours after surgery
Persistent neurologic deficit
Time Frame: 7 days post surgery
Presence of persistent sensory or motor postoperative deficit
7 days post surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 16, 2018

Primary Completion (Actual)

April 30, 2019

Study Completion (Actual)

April 30, 2019

Study Registration Dates

First Submitted

July 4, 2018

First Submitted That Met QC Criteria

July 31, 2018

First Posted (Actual)

August 1, 2018

Study Record Updates

Last Update Posted (Actual)

May 1, 2019

Last Update Submitted That Met QC Criteria

April 29, 2019

Last Verified

April 1, 2019

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain, Postoperative

Clinical Trials on Dexamethasone

3
Subscribe